正文：
近日，今年医保药品目录调整工作正式启动，引起了业内的广泛关注。对此，药企方面表示，当前政策更加规范透明，给企业带来了稳定的预期。
6月30日，迪哲医药副总经理、首席商务官吴清漪在接受澎湃新闻记者采访时表示：“目前，我们看到政策越来越规范，越来越透明。规则的可控性对于企业发展至关重要。”吴清漪认为，所有行业都需要对未来有一个稳定的预期，而可预测性对于企业的发展尤为重要。
据了解，此次医保药品目录调整工作的启动，旨在进一步优化医疗保障制度，更好地满足广大患者的用药需求。相关药企也对此表示积极响应，认为政策的规范透明，不仅有利于企业的长远发展，也有利于提高药品的质量，推动行业向更加健康的方向发展。
此次医保药品目录调整工作的启动，将对我国医药行业产生深远影响。期待相关政策的实施，能够为患者带来更为优质的医疗服务，为药企创造更加稳定的发展环境。
英语如下：
News Title: Adjustment of Medical Insurance Drug Directory Starts: Policy Norms and Transparency, Industry Expects Stability
Keywords: adjustment of medical insurance drug directory, policy norms and transparency, drug companies expect stability
News Content:
News Title: Adjustment of Medical Insurance Drug Directory Starts, Drug Companies Say Policies Are More Standardized and Transparent
Recently, the adjustment of the medical insurance drug directory has been officially launched, attracting widespread attention in the industry. In response, drug companies said that current policies are more standardized and transparent, bringing stable expectations to enterprises.
On June 30th, Wu Qingyi, the deputy general manager and chief business officer of Di Zhe Pharmaceutical, said in an interview with The Paper: “Currently, we see policies becoming more standardized and transparent. The controllability of rules is crucial for enterprise development.” Wu believes that all industries need a stable expectation for the future, and predictability is particularly important for enterprise development.
It is understood that the adjustment of the medical insurance drug directory is aimed at further optimizing the medical security system to better meet the medication needs of patients. Related drug companies have also responded positively, believing that the standardization and transparency of policies are not only conducive to the long-term development of enterprises, but also help to improve the quality of drugs and promote the industry to develop in a more healthy direction.
The adjustment of the medical insurance drug directory will have a profound impact on China’s pharmaceutical industry. It is expected that the implementation of relevant policies will bring better medical services to patients and create a more stable development environment for drug companies.
【来源】http://www.chinanews.com/life/2024/07-01/10243638.shtml
Views: 3